8:50AM BioDelivery Sciences receives patent allowance triggering $15 mln milestone payment from Endo Pharmaceuticals (ENDP) (BDSI) 2.00 : Co announced the U.S. Patent and Trademark Office has issued a Notice of Allowance of BDSI's patent application (No. 13/184306) that, once formally granted, will extend the exclusivity of the BioErodible MucoAdhesive drug delivery technology for BEMA Buprenorphine and BEMA Buprenorphine/Naloxone from 2020 to 2027. As a part of BDSI's recently signed BEMA Buprenorphine licensing and development agreement with Endo Pharmaceuticals (ENDP), BDSI is entitled to a milestone payment in the amount of $15 mln upon the final granting of this patent. BDSI expects the final granting of the patent and associated payment of the $15 mln milestone within the next few months.
Market Data 
Markets 
AI
